One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Infectious Disease Drugs Market

[ 英語タイトル ] Infectious Disease Drugs Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0089107
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 111
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - AbbVie Inc.
- Boehringer Ingelheim GmbH
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- Janssen Pharmaceutical (Johnson & Johnson)
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Takeda Pharmaceutical Company Limited

[Report Description]

The major factors for the growth of the infectious disease drugs market include the rising awareness activities by various government and non-profit organizations, increasing prevalence of infectious diseases, and the rising funding for the research and development.

The rising prevalence of infectious diseases is expected to boost the overall growth of the market over the forecast period. According to the World Health Organization (WHO), it is estimated that in 2018, nearly 37.9 million individuals had HIV, globally. It has been identified that most of this prevalence is in low and middle-income countries, with an estimated 66% living in Sub-Saharan Africa.

Similarly, as per the WHO’s 2017 Global Tuberculosis Report, approximately 6.3 million new cases of tuberculosis (TB) were reported in 2016. The report also estimated that the new cases corresponded to 61% of the estimated incidence of 10.4 million TB cases. Thus, rising cases of infectious diseases are expected to increase the demand for infectious drugs resulting in the high growth of the market.

Key Market Trends

Malaria Segment is Expected to Hold a Significant Market Share over the Forecast Period

The high prevalence of malaria and other infections; increasing incidence of these conditions; and rising expenditure on the prevention and diagnosis of infectious diseases are likely to be the key factors responsible for the growth of this market. According to the WHO Report, Africa has been found to have the highest rate of malaria. Therefore, between 2000 and 2015, an expansion of malaria interventions has helped to reduce malaria incidence by 37% globally, and by 42% in Africa.

There are also various initiatives focusing on disease prevention are being undertaken globally. Furthermore, the government, private, and nonprofit organizations are also focusing on increasing the management of these diseases. Hence all these factors are expected to drive the overall market growth.

North America is Expected to Hold Largest Market Share over the Forecast Period

The United States is expected to be the largest infectious disease drug market owing to the rising prevalence of infectious diseases and the presence of better healthcare infrastructure. As per the Centers for Disease Control and Prevention (CDC), in 2017, a total of 9,093 new cases of tuberculosis (TB) were reported in the United States, representing an incidence rate of 2.8 cases per 100,000 population.

Furthermore, the antibiotic prescription rate is relatively high in the United States. In addition, the trend varies significantly, based on the provider in a particular state. Also, there is a rising prevalence of HIV in the United States and there is a rise in approval for the new disease treatment which is expected to boost the growth of the market. Thus, owing to the all above mentioned factors the market is expected to witness high growth over the forecast period.

Competitive Landscape

The market studied is a fragmented market owing to the presence of various market players. Some of the market players are AbbVie Inc, Boehringer Ingelheim GmbH, Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceutical, Merck & Co., Inc., Novartis AG, Pfizer Inc, Sanofi SA, and Takeda Pharmaceutical Company Limited.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Awareness Activities by Various Government and Non-profit Organizations
4.2.2 Increasing Prevalence of Infectious Diseases
4.2.3 Rising Funding for the Research and Development
4.3 Market Restraints
4.3.1 Low Penetration Rates of Diagnosis and Treatment in Developing Countries
4.3.2 Side Effects of the Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Disease
5.1.1 HIV
5.1.2 Influenza
5.1.3 Hepatitis
5.1.4 Tuberculosis
5.1.5 Malaria
5.1.6 Other
5.2 By Treatment
5.2.1 Antibacterial
5.2.2 Antiviral
5.2.3 Antiparasitic
5.2.4 Other
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Boehringer Ingelheim GmbH
6.1.3 Gilead Sciences, Inc.
6.1.4 GlaxoSmithKline plc
6.1.5 Janssen Pharmaceutical (Johnson & Johnson)
6.1.6 Merck & Co., Inc.
6.1.7 Novartis AG
6.1.8 Pfizer Inc.
6.1.9 Sanofi SA
6.1.10 Takeda Pharmaceutical Company Limited




Recommended reports